Zaleplon is a pyrazolopyrimidine derivative and possesses sedative and hypnotic properties. Seven unknown impurities in zaleplon bulk drug at levels below 0.1% were detected by reverse-phase high performance liquid chromatography (HPLC). The starting material, 3-amino-4-cyanopyrazole and an intermediate, N-[3-[3-(dimethylamino)-1-oxo-2-propenyl]-phenyl]-N-ethylacetamide (DOPEA) were also present in the sample at a level below 0.1%. The molecular weights of impurities were determined by LC-MS analysis. These impurities were isolated from crude samples of zaleplon using reverse-phase preparative HPLC. Based on the spectral data the structures of these impurities were characterized as, N-(3-(3-(4-amino-2H-pyrazolo [3,4-d]pyrimidin-6-yl) pyrazolo[1,5-a] pyrimidin-7-yl)phenyl)-N-ethylacetamide (impurity I); N-[3-(3-carboxamidopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide (impurity II); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]acetamide (impurity III); N-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-N-methylacetamide (impurity IV); N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-5-yl)phenyl]-N-ethylacetamide (impurity V); N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl)phenyl]-N-ethylamine (impurity VI); N-[3-(3-cyano-6-[(E)-3-((N-ethyl-N-acetyl)amino)phenyl-3-oxoprop-1-enyl] pyrazolo[1,5-a]pyrimidin-7-yl) phenyl]-N-ethylacetamide (impurity VII). Structural elucidation of all impurities by spectral data ((1)H NMR, (13)C NMR, MS and IR) and formation of these impurities are discussed in detail.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2007.01.051 | DOI Listing |
Pharmaceutics
November 2024
State Research Center-Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Zhivopisnaya Str., Bld. 46, 123098 Moscow, Russia.
Background: Radiochemical purity is a key criterion for the quality of radiopharmaceuticals used in clinical practice. The joint improvement of analytical methods capable of identifying related radiochemical impurities and determining the actual radiochemical purity, as well as the improvement of synthesis methods to minimize the formation of possible radiochemical impurities, is integral to the implementation of high-tech nuclear medicine procedures. PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for prostate cancer, and [Lu]Lu-PSMA-617 and [Lu]Lu-PSMA have achieved global recognition as viable radiopharmaceuticals.
View Article and Find Full Text PDFPharmaceutics
November 2024
Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Kanagawa, Japan.
Extracellular vesicles (EVs), including exosomes, are promising pharmaceutical modalities. They are purified from cell culture supernatant; however, the preparation may contain EVs with the desired therapeutic effects and different types of EVs, lipoproteins, and soluble proteins. Evaluating the composition of particulate impurities and the levels of protein impurities in final preparations is critical for quality control.
View Article and Find Full Text PDFMolecules
December 2024
Chengdu Shibeikang Biomedical Technlogy Co., Ltd., 26-1-2, No.2 Tianyu Road, Chendu Gaoxin West District, Chengdu 611700, China.
A new process route suitable for the industrial production of BAY2433334 has been developed in this paper, which avoids the patent limitations of the originator company of BAY2433334 to the preparation of BAY2433334. BAY2433334 is obtained from (2)-2-aminobutyric acid by esterification, diazotization, condensation reactions, deacetyl deprotection, activation reactions, and Mitsunobu reactions. This method is simple to operate, and the raw materials are inexpensive and readily available.
View Article and Find Full Text PDFMolecules
December 2024
Faculty of Non-Ferrous Metals, AGH University of Krakow, Al. Mickiewicza 30, 30-059 Krakow, Poland.
Gallium, a critical and strategic material for advanced technologies, is anomalously enriched in certain coal deposits and coal by-products. Recovering gallium from solid residues generated during coal production and utilization can yield economic benefits and positive environmental gains through more efficient waste processing. This systematic literature review focuses on gallium concentrations in coal and its combustion or gasification by-products, modes of occurrence, gallium-hosting phases, and hydrometallurgical recovery methods, including pretreatment procedures that facilitate metal release from inert aluminosilicate minerals.
View Article and Find Full Text PDFMolecules
December 2024
CP2M-ESCPE Lyon, CNRS, University Claude Bernard Lyon 1, UMR 5128, 43 Bd du 11 Nov. 1918, CEDEX, 69616 Villeurbanne, France.
TiO:Eu nanoparticles with varying europium concentrations were successfully synthesized via a one-pot sol-gel approach using a molecular heterometallic single-source precursor (SSP) Eu-Ti. For comparison, nanomaterials with similar europium levels were also produced by impregnating europium salts onto the same TiO substrate. All the nanomaterials were thoroughly characterized using Eu elemental analysis, powder X-ray diffraction (XRD), scanning (SEM), transmission (TEM), scanning transmission electron microscopy (STEM), Brunauer-Emmett-Teller (BET) analysis, thermogravimetric analysis (TGA), X-ray photoelectron spectroscopy (XPS), Raman spectroscopy, and photoluminescence (PL).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!